Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area

This study investigates the efficacy of a sustained-release (SR) moxidectin microsphere formulation in preventing canine heartworm infection over 18 months in Canary Hound dogs, a hunting breed common in the Canary Islands, which is a hyperendemic region. These dogs typically do not receive preventi...

Full description

Saved in:
Bibliographic Details
Main Authors: Agustina Isabel Quintana-Mayor, Elena Carretón, José Alberto Montoya-Alonso
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Animals
Subjects:
Online Access:https://www.mdpi.com/2076-2615/14/20/3001
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850205705361948672
author Agustina Isabel Quintana-Mayor
Elena Carretón
José Alberto Montoya-Alonso
author_facet Agustina Isabel Quintana-Mayor
Elena Carretón
José Alberto Montoya-Alonso
author_sort Agustina Isabel Quintana-Mayor
collection DOAJ
description This study investigates the efficacy of a sustained-release (SR) moxidectin microsphere formulation in preventing canine heartworm infection over 18 months in Canary Hound dogs, a hunting breed common in the Canary Islands, which is a hyperendemic region. These dogs typically do not receive preventive treatments and act as reservoirs for the disease. This field study was conducted across 11 hunting kennels with 109 dogs living outdoors, none of whom were receiving heartworm prophylaxis, with <i>Dirofilaria immitis</i> prevalence ranging from 11.1% to 57.1% (average 36.7%). Among these, 20 clinically healthy, heartworm-negative dogs were randomly selected to receive a single subcutaneous injection of moxidectin SR (0.17 mg/kg body weight). Antigen and Knott’s tests were performed at 6, 12, 18, and 24 months. All dogs completed the study without adverse reactions and remained heartworm-negative throughout. By the end of the study, kennel heartworm prevalence ranged from 14.3% to 46.7% (average 35.4%). A single subcutaneous dose of moxidectin SR at the recommended dosage may prevent patent heartworm infection in dogs for up to 18 months in hyperendemic regions. Further studies are required to confirm these findings. Extending the efficacy period of moxidectin could improve owner compliance, particularly among those with lower animal health awareness.
format Article
id doaj-art-14a03a2ba3a642c3b03e29be2ecbf3dd
institution OA Journals
issn 2076-2615
language English
publishDate 2024-10-01
publisher MDPI AG
record_format Article
series Animals
spelling doaj-art-14a03a2ba3a642c3b03e29be2ecbf3dd2025-08-20T02:11:01ZengMDPI AGAnimals2076-26152024-10-011420300110.3390/ani14203001Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic AreaAgustina Isabel Quintana-Mayor0Elena Carretón1José Alberto Montoya-Alonso2“El Parque” Veterinary Center, C/ María Encarnación Navarro no. 42 Local Bajo, 35200 Telde, SpainInternal Medicine, Veterinary Medicine and Therapeutic Research Group, Faculty of Veterinary Medicine, Research Institute of Biomedical and Health Sciences (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), 35016 Las Palmas de Gran Canaria, SpainInternal Medicine, Veterinary Medicine and Therapeutic Research Group, Faculty of Veterinary Medicine, Research Institute of Biomedical and Health Sciences (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), 35016 Las Palmas de Gran Canaria, SpainThis study investigates the efficacy of a sustained-release (SR) moxidectin microsphere formulation in preventing canine heartworm infection over 18 months in Canary Hound dogs, a hunting breed common in the Canary Islands, which is a hyperendemic region. These dogs typically do not receive preventive treatments and act as reservoirs for the disease. This field study was conducted across 11 hunting kennels with 109 dogs living outdoors, none of whom were receiving heartworm prophylaxis, with <i>Dirofilaria immitis</i> prevalence ranging from 11.1% to 57.1% (average 36.7%). Among these, 20 clinically healthy, heartworm-negative dogs were randomly selected to receive a single subcutaneous injection of moxidectin SR (0.17 mg/kg body weight). Antigen and Knott’s tests were performed at 6, 12, 18, and 24 months. All dogs completed the study without adverse reactions and remained heartworm-negative throughout. By the end of the study, kennel heartworm prevalence ranged from 14.3% to 46.7% (average 35.4%). A single subcutaneous dose of moxidectin SR at the recommended dosage may prevent patent heartworm infection in dogs for up to 18 months in hyperendemic regions. Further studies are required to confirm these findings. Extending the efficacy period of moxidectin could improve owner compliance, particularly among those with lower animal health awareness.https://www.mdpi.com/2076-2615/14/20/3001<i>Dirofilaria immitis</i>heartwormchemoprophylaxiscaninemacrocyclic lactonesmoxidectin
spellingShingle Agustina Isabel Quintana-Mayor
Elena Carretón
José Alberto Montoya-Alonso
Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
Animals
<i>Dirofilaria immitis</i>
heartworm
chemoprophylaxis
canine
macrocyclic lactones
moxidectin
title Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
title_full Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
title_fullStr Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
title_full_unstemmed Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
title_short Efficacy of Sustained-Release Formulation of Moxidectin (Guardian SR) in Preventing Heartworm Infection over 18 Months in Dogs Living in a Hyperendemic Area
title_sort efficacy of sustained release formulation of moxidectin guardian sr in preventing heartworm infection over 18 months in dogs living in a hyperendemic area
topic <i>Dirofilaria immitis</i>
heartworm
chemoprophylaxis
canine
macrocyclic lactones
moxidectin
url https://www.mdpi.com/2076-2615/14/20/3001
work_keys_str_mv AT agustinaisabelquintanamayor efficacyofsustainedreleaseformulationofmoxidectinguardiansrinpreventingheartworminfectionover18monthsindogslivinginahyperendemicarea
AT elenacarreton efficacyofsustainedreleaseformulationofmoxidectinguardiansrinpreventingheartworminfectionover18monthsindogslivinginahyperendemicarea
AT josealbertomontoyaalonso efficacyofsustainedreleaseformulationofmoxidectinguardiansrinpreventingheartworminfectionover18monthsindogslivinginahyperendemicarea